Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may reduce the risk of developing cancer-related lymphedema following axillary lymph node dissection (ALND)
PurposePatients undergoing axillary lymph node dissection (ALND) for breast cancer face a high risk of lymphedema, further increased by high body mass index (BMI) and insulin resistance. GLP-1 receptor agonists (GLP-1RAs) have the potential to reduce these risk factors, but their role in lymphedema...
Saved in:
Main Authors: | Stav Brown (Author), Audree B. Tadros (Author), Giacomo Montagna (Author), Tajah Bell (Author), Fionnuala Crowley (Author), Emily J. Gallagher (Author), Joseph H. Dayan (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2024-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations
by: Dan Xu, et al.
Published: (2022) -
Glucagon-like peptide 1 (GLP-1)
by: T.D. Müller, et al.
Published: (2019) -
Doxycycline for the treatment of breast cancer-related lymphedema
by: Stav Brown, et al.
Published: (2022) -
Pharmacological Treatment of Secondary Lymphedema
by: Stav Brown, et al.
Published: (2022) -
Effects of exercise on glucagon-like peptide-1 (GLP-1)
by: Shin-ya Ueda, et al.
Published: (2013)